Study Finds FDA Rx Actions Suspicious

| From

LOS ANGELES, Calif. /Send2Press Newswire/ -- Dr. Gary Lawson announced the results of a two-year study showing that the large sums of money paid yearly to the Food and Drug Administration (FDA) by the brand name pharmaceutical manufacturers gives the drug industry financial leverage and influence over the FDA. The study concluded that until the drug industry money or the strings attached to the money are eliminated, U.S. citizens should be extremely cautious and highly suspicious of FDA actions related to prescription drugs.

In 1992, to speed up new drug approvals and eliminate a backlog of needed life-saving medications, Congress authorized the collection of drug industry fees for one five-year period. Although no new drug approval efficiencies were realized after year five, the law was extended twice. According to the ULV study, with each extension, the drug industry paid significantly higher fees, and then, used the higher fees as leverage to limit the FDA's ability to act as an objective consumer protection agency.

As the brand name drug industry acquired more financial leverage over the FDA, the ULV study showed that adverse drug reaction reports more than doubled. Americans have a 32% higher chance of experiencing a reportable adverse drug reaction. More deadly drugs were released in the U.S. first and stayed on the U.S. market longer. The costs of drugs to consumers skyrocketed. The FDA shifted its policy to protect the drug industry's U.S. monopoly, and actively worked toward stopping the flow of lower cost Canadian medications.

Off-label drug promotion was authorized. Direct to consumer advertising was authorized. The FDA significantly decreased other consumer protection services, and the FDA allowed the drug industry to set internal Agency objectives, goals, and FDA job descriptions.

For more information see

News Source:
Like, Share, Save this press release:
  TWEET   SHARE   G+   STUMBLE   LinkedIn   Instapaper   Buffer

The content of the above press release was provided by the “news source” (Lawson Health Care Foundation) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2005 Lawson Health Care Foundation with newswire version Copr. © 2005 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Oct 28 2016:
[ count retired 8.4.16 ]

or: Search

back to top
REFERENCES: , , Gary W. Lawson, Ph.D., DPA, Lawson Health Care Foundation, FDAs,FDA study,FDA drug approvals, FDA approved drugs, medicines, medications, PDUFA, user fees, drug industry, CDER, drug safety,drug approvals, drug withdrawals,safety medications, news, press release from Lawson Health Care Foundation, Mar 16, 2005, Health, Diet and Fitness, , , , , Study Finds FDA Rx Actions Suspicious